Mr. Wilson has more than 15 years of clinical research experience across phase 1 through phase 3 studies in an array of therapeutic areas including, CNS, infectious disease, and women’s health, with a primary focus on oncology and hematology. As Clinical Team Lead, he provided oversight in AML Phase I 3×3 dose escalation cohort studies, global Phase II and III breast and cervical cancer solid tumor trials, as well as prostate cancer trials. Mr. Wilson built strong relationships with over 60 of the leading oncology and academic sites in the US and worked alongside a major oncology sponsor in an initiative to engage and grow relationships with large oncology SMOs to understand their processes and people. As a result of this initiative, start-up times were reduced by 40% for their network sites. Throughout his years in oncology research, Mr. Wilson has worked on multiple studies that have included RECIST 1.0, RECIST 1.1, ECOG, WHO and FAB classification, Cytogenetics, and reviewing multiple biomedical imaging techniques, reports, and biomarkers.

Mr. Wilson has served in many leadership roles during his time in the industry including Sr. Site Activation Specialist, Manager Start-up and Functional Services, Clinical Team Lead, Clinical Operations Lead, and Associate Director of Study Start-up. He has worked in functional and full-service models in start-up and clinical roles, providing him with cross functional expertise and the holistic acumen of developing a successful oncology clinical trial.

At Rho, Mr. Wilson oversees a team of highly skilled professionals in the start-up team accelerating clinical trials from feasibility through to activation. He has been involved with the development of site essential document guidelines and packages, case report forms and other data collections forms, informed consent forms, site and monitor training tools, clinical monitoring plans, as well as guidance documents and SOPs for start-up and clinical personnel.

Mark Wilson obtained a bachelor’s in chemistry from North Carolina State University.

Why Oncology?

“I have seen the devastating impact cancer can have on families. When I first moved to the CRO industry I immediately got a chance to work on oncology trials as a Start-up associate and lead. I enjoyed the challenge these trials presented and was inspired by the aims of these studies and the possibility of positive outcomes for patients and families. After moving to the CRA role I worked briefly across other indications, however I found oncology most satisfying and quickly moved back to these trials working as a CRA and later as a Clinical Operations lead.”

This is what drives Mark:

“The people and teams I work with are my number one driver. I enjoy leading teams in the complex work required to bring a trial to patients and ultimately a drug to market. Even though I am often far separated from the individuals for which clinical trials are life changing and lifesaving, simply knowing the impact of these studies drives me to add my small contribution to creating a healthier world.”